[Electroencephalographic abnormalities during treatment with psychopharmacological agents].
D014151:Anti-Anxiety Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects*; D003024:Clozapine / Q000009:adverse effects; D004562:Electrocardiography; D006801:Humans; D007099:Imipramine / Q000009:adverse effects; D008094:Lithium / Q000009:adverse effects* / Q000627:therapeutic use; D008376:Maprotiline / Q000009:adverse effects; D001523:Mental Disorders / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use; D012640:Seizures / Q000139:chemically induced
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D011619:Psychotropic Drugs; D008376:Maprotiline; D008094:Lithium; D003024:Clozapine; D007099:Imipramine
Anomalie elettroencefalografiche durante il trattamento con psicofarmaci.